Eupraxia Pharmaceuticals Inc.
EPRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$7.08
KIRA · Stoqly’s AI analyst, in plain words
- Eupraxia Pharmaceuticals Inc. had $0.0M of revenue in fiscal 2025.
- Eupraxia Pharmaceuticals Inc. lost $38.6M in fiscal 2025.
Market cap
$283M
P/E
—
Revenue
$0.0M
Net income
−$38.6M
Free cash flow
—
Operating margin
—
Eupraxia Pharmaceuticals Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$38.6M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Eupraxia Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 40-F · Mar 13, 2026
- Legal name
- EUPRAXIA PHARMACEUTICALS INC.
- CIK
- 0001581178
Eupraxia Pharmaceuticals Inc. · EPRX
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | — | $0.0M | $0.0M | $0.0M |
| Net income | −$18.5M | −$28.2M | −$25.5M | −$38.6M |
| Diluted EPS | −$0.96 | −$1.17 | −$0.76 | −$1.03 |
| Cash | ||||
| Cash from operations | −$14.4M | −$20.7M | −$30.0M | −$28.6M |
| Share count change | — | 25.2% | 40.5% | 17.8% |
| Debt and strength | ||||
| Cash and short-term investments | $18.3M | $19.3M | $33.1M | $80.6M |
| Shareholders' equity | $7.8M | $2.2M | $33.4M | $82.0M |
| Current ratio | 6.1x | 1.0x | 11.1x | 15.1x |
| Returns and quality | ||||
| Return on equity | −237.5% | −564.3% | −143.2% | −66.8% |
| Return on tangible equity | −237.5% | −1,273.4% | −76.3% | −47.0% |
| Piotroski F-score | — | — | 2 | 3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Eupraxia Pharmaceuticals Inc. · EPRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.08 a share, the company is worth $283M.
Source: SEC EDGAR XBRL filings (CIK 0001581178). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.